{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:01:01Z","timestamp":1761058861695},"reference-count":10,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,10,29]],"date-time":"2008-10-29T00:00:00Z","timestamp":1225238400000},"content-version":"vor","delay-in-days":4625,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1996,3]]},"abstract":"<jats:p>With the future advent of a world wide ban on chlorofluorocarbon containing aerosols, a study was designed to compare the <jats:italic>in vivo<\/jats:italic> lung bioavailability of salbutamol via chlorofluorocarbon\u2010containing metered\u2010dose inhaler (CFC), chlorofluorocarbon\u2010free metered\u2010dose inhaler (CFC\u2010free), and dry powder inhaler (DPI). Twelve healthy male subjects were given 1200 \u03bcg salbutamol and measurements made of plasma and urinary salbutamol. CFC\u2010free produced significantly higher plasma salbutamol levels (ng ml<jats:sup>\u20101<\/jats:sup>; mean and 95% CI for difference) than either CFC or DPI: C<jats:sub>max<\/jats:sub>, CFC\u2010free 4.18 <jats:italic>vs<\/jats:italic> CFC 3.29 (95% CI 0.10\u20131.68), <jats:italic>vs<\/jats:italic> DPI 3.42 (95% CI \u20100.03\u20131.56). The ratio for the difference in C<jats:sup>max<\/jats:sup> between CFC and CFC\u2010free formulations was 1.32 (95% CI 1.02\u20131.61). There were no significant differences between CFC and DPI formulations. Urinary salbutamol results did not reveal any significant differences between the three inhalers (\u03bcg 30 min<jats:sup>\u20101<\/jats:sup>): CFC\u2010free 42.4, CFC 43.8, DPI 45.3. Thus, the lung bioavailibility of CFC\u2010free was greater than that of CFC or DPI formulations of salbutamol.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1996.tb00191.x","type":"journal-article","created":{"date-parts":[[2008,10,29]],"date-time":"2008-10-29T15:22:59Z","timestamp":1225293779000},"page":"247-249","source":"Crossref","is-referenced-by-count":35,"title":["Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol"],"prefix":"10.1111","volume":"41","author":[{"given":"D. J.","family":"CLARK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. J.","family":"LIPWORTH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,10,29]]},"reference":[{"key":"e_1_2_1_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(05)80060-5"},{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.48.5.506"},{"issue":"79","key":"e_1_2_1_3_2","first-page":"18","article-title":"A new generation of inhaler technology","author":"June D.","year":"1995","journal-title":"Br J Clin Practice"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb05921.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558154"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00562546"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb00393.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.103.5.1442"},{"issue":"79","key":"e_1_2_1_9_2","first-page":"13","article-title":"Technological development of airomir (salbutamol sulphate in CFC free system) MDI","author":"Tansey I.","year":"1995","journal-title":"Br J Clin Practice"},{"issue":"19","key":"e_1_2_1_10_2","first-page":"259s","article-title":"Lung bioavailability of generic and innovator formulations of inhaled salbutamol","volume":"8","author":"Clark DJ","year":"1995","journal-title":"Eur Resp J"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1996.tb00191.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1996.tb00191.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1996.tb00191.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T22:27:17Z","timestamp":1698359237000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1996.tb00191.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1996,3]]}},"alternative-id":["10.1111\/j.1365-2125.1996.tb00191.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1996.tb00191.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,3]]}}}